In dedicated experimental models of allogeneic hematopoietic stem cell transplantation the authors evaluated side-by-side the therapeutic effect of two IL-2/anti-IL-2 complexes designed either to boost Tregs, or alternatively to activate effector T cells Teffs, on GVHD occurrence and tumor relapse.
[Haematologica]